Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Harvard Business School
Moodys
Merck

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR SORAFENIB TOSYLATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Sorafenib Tosylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00093457 ↗ Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2004-07-21 RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients who have metastatic or recurrent prostate cancer that has not responded to previous hormone therapy.
NCT00093457 ↗ Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer Completed NCIC Clinical Trials Group Phase 2 2004-07-21 RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients who have metastatic or recurrent prostate cancer that has not responded to previous hormone therapy.
NCT00093613 ↗ Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma Completed National Cancer Institute (NCI) Phase 1 2004-12-01 This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sorafenib Tosylate

Condition Name

Condition Name for Sorafenib Tosylate
Intervention Trials
Liver Cancer 17
Stage IV Renal Cell Cancer 10
Unspecified Adult Solid Tumor, Protocol Specific 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sorafenib Tosylate
Intervention Trials
Carcinoma 41
Carcinoma, Hepatocellular 30
Liver Neoplasms 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sorafenib Tosylate

Trials by Country

Trials by Country for Sorafenib Tosylate
Location Trials
United States 812
Canada 45
Australia 8
France 7
China 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sorafenib Tosylate
Location Trials
California 34
Texas 33
Illinois 33
Ohio 33
New York 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sorafenib Tosylate

Clinical Trial Phase

Clinical Trial Phase for Sorafenib Tosylate
Clinical Trial Phase Trials
Phase 3 12
Phase 2/Phase 3 1
Phase 2 83
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sorafenib Tosylate
Clinical Trial Phase Trials
Completed 103
Terminated 25
Active, not recruiting 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sorafenib Tosylate

Sponsor Name

Sponsor Name for Sorafenib Tosylate
Sponsor Trials
National Cancer Institute (NCI) 121
Bayer 13
Alliance for Clinical Trials in Oncology 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sorafenib Tosylate
Sponsor Trials
Other 140
NIH 121
Industry 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKesson
Merck
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.